Cardiogenic shock secondary prevention
|
Cardiogenic Shock Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cardiogenic shock secondary prevention On the Web |
|
American Roentgen Ray Society Images of Cardiogenic shock secondary prevention |
|
Risk calculators and risk factors for Cardiogenic shock secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2] Syed Musadiq Ali M.B.B.S.[3] James Nasr[4]
Cardiogenic shock secondary prevention
Overview
Secondary prevention after cardiogenic shock includes interventions after the acute event to prevent recurrent cardiovascular events, recurrent or progressive heart failure, recurrent shock, rehospitalization, arrhythmia, renal dysfunction, neurocognitive impairment, and death. Survivors require structured transition from acute stabilization to recovery-focused care, including guideline-directed medical therapy, antiplatelet and antithrombotic therapy when indicated, lipid lowering, cardiac rehabilitation, device therapy evaluation, risk-factor modification, palliative-care integration when appropriate, and close post-discharge follow-up.[1][2]
This microchapter focuses on prevention after survival of cardiogenic shock. Acute vasoactive therapy, temporary mechanical circulatory support, and surgical or procedural therapy are addressed in the medical therapy and surgery microchapters.
Guideline-directed medical therapy for heart failure
Principles
Survivors of cardiogenic shock with reduced left ventricular ejection fraction should be transitioned to guideline-directed medical therapy when hemodynamically tolerated. The four foundational medication classes for heart failure with reduced ejection fraction are renin-angiotensin system inhibition, preferably an angiotensin receptor-neprilysin inhibitor when feasible; an evidence-based beta blocker; a mineralocorticoid receptor antagonist; and an SGLT2 inhibitor.[3][4]
Guideline-directed therapy should usually be initiated before discharge when blood pressure, perfusion, renal function, potassium, volume status, and rhythm permit. Initiation should be paired with a clear outpatient titration plan rather than delayed indefinitely until full recovery.[3][5]
Evidence in cardiogenic shock survivors
In the FRENSHOCK registry of 535 cardiogenic shock survivors, discharge triple therapy with a beta blocker, renin-angiotensin system inhibitor, and mineralocorticoid receptor antagonist was associated with lower 1-year all-cause mortality compared with non-triple therapy (adjusted HR 0.44; 95% CI 0.19-0.80; P=0.007). Mortality decreased stepwise as the number of heart failure drug classes increased.[2]
A separate FRENSHOCK analysis reported that patients who did not discontinue pre-existing beta-blockers within 24 hours of cardiogenic shock had lower 1-month mortality (adjusted HR 0.43; 95% CI 0.20-0.92; P=0.03). Early introduction of new beta-blocker therapy did not show the same outcome reduction. These findings support cautious continuation or early reintroduction only when hemodynamically feasible, not beta-blocker use during active unstable shock.[6]
Practical GDMT initiation after cardiogenic shock
| Drug class | When to initiate or restart | Key considerations |
|---|---|---|
| ARNI, ACE inhibitor, or ARB | When off vasopressors, blood pressure tolerates initiation, renal function is stable or near baseline, and potassium is acceptable | ARNI is preferred over ACE inhibitor or ARB when feasible. A 36-hour washout is required after ACE inhibitor before starting ARNI. Start low and titrate.[3] |
| Evidence-based beta blocker | When euvolemic, off inotropes and vasopressors, and heart rate and blood pressure permit | Use carvedilol, metoprolol succinate, or bisoprolol. Avoid during active shock, ongoing decompensated heart failure, significant bradycardia, or high-grade atrioventricular block.[7] |
| Mineralocorticoid receptor antagonist | When renal function and potassium are stable and follow-up laboratory monitoring is feasible | Minimal blood pressure effect; monitor potassium and creatinine closely.[3] |
| SGLT2 inhibitor | When blood pressure, renal function, oral intake, and volume status permit | Minimal blood pressure effect and no titration required. Assess risk of volume depletion, ketoacidosis, and genital mycotic infection.[3] |
Antiplatelet and antithrombotic therapy
For cardiogenic shock due to acute coronary syndrome, antiplatelet therapy should follow contemporary ACS and PCI recommendations while accounting for bleeding risk from shock, vascular access, mechanical circulatory support, renal dysfunction, hepatic injury, and coagulopathy.
The 2025 ACC/AHA/ACEP/NAEMSP/SCAI acute coronary syndromes guideline recommends dual antiplatelet therapy with aspirin and an oral P2Y12 inhibitor for at least 12 months as the default strategy in patients with ACS who are not at high bleeding risk. Ticagrelor or prasugrel is preferred over clopidogrel in patients undergoing PCI when not contraindicated.[8]
Bleeding-reduction strategies after ACS-PCI include proton pump inhibitor use for gastrointestinal bleeding risk, selected early aspirin discontinuation with P2Y12 inhibitor monotherapy, and shortened or modified antithrombotic regimens in patients requiring long-term oral anticoagulation.[8]
For chronic coronary disease without another indication for oral anticoagulation, low-dose aspirin 81 mg daily, or 75-100 mg daily, is recommended indefinitely.[9][10]
Lipid management
High-intensity statin therapy is recommended after ACS unless contraindicated. The 2025 ACS guideline recommends high-intensity statin therapy for all patients with ACS, with the option to initiate concurrent ezetimibe. A nonstatin lipid-lowering agent is recommended when LDL-C remains ≥70 mg/dL despite maximally tolerated statin therapy (class 1, level A), with addition also reasonable at LDL-C 55-69 mg/dL in selected patients (class 2a, level B-R).[8]
The 2026 ACC/AHA dyslipidemia guideline further stratifies LDL-C goals by ASCVD risk. Most acute myocardial infarction-related cardiogenic shock survivors meet very high-risk ASCVD criteria, for which more intensive LDL-C lowering is recommended. Escalation beyond statin therapy should prioritize agents with completed cardiovascular outcomes evidence, including ezetimibe, PCSK9 monoclonal antibodies, and bempedoic acid when clinically appropriate.[11][12]
Inclisiran lowers LDL-C but cardiovascular outcomes trials are ongoing. The 2026 ACC/AHA dyslipidemia guideline gives inclisiran a more limited role, generally for patients unable to tolerate or obtain PCSK9 monoclonal antibodies; it should not be presented as having the same completed outcomes evidence as ezetimibe, PCSK9 monoclonal antibodies, or bempedoic acid.[13][8]
The 2026 dyslipidemia guideline gives lipoprotein(a) measurement a class 1 recommendation at least once in all adults for ASCVD risk assessment. This is particularly relevant in cardiogenic shock survivors with atherosclerotic etiology or premature, recurrent, or unexplained coronary events.[11]
Beta-blocker therapy after myocardial infarction
Beta blockers remain a core therapy for patients with reduced LVEF or heart failure after myocardial infarction and should be used as part of GDMT when tolerated. However, long-term beta-blocker benefit after revascularized myocardial infarction with preserved LVEF is uncertain.
The REDUCE-AMI trial of 5,020 patients with acute myocardial infarction and preserved LVEF ≥50% found no benefit of long-term beta-blocker therapy for the composite of death from any cause or new myocardial infarction (HR 0.96; 95% CI 0.79-1.16; P=0.64).[14]
An individual-patient-data meta-analysis of contemporary trials also found no clear benefit of beta-blocker therapy after recent myocardial infarction with preserved LVEF.[15]
For cardiogenic shock survivors whose LVEF remains reduced, evidence-based beta blockers remain indicated when tolerated. For patients whose LVEF recovers to ≥50% after revascularization and stabilization, beta-blocker duration should be individualized based on LVEF, arrhythmia risk, recurrent ischemia, blood pressure, and heart failure status.[14][15]
SGLT2 inhibitors after acute myocardial infarction
SGLT2 inhibitors are recommended as part of GDMT for patients with HFrEF regardless of diabetes status.[3][4] The 2025 ACS guideline states that SGLT2 inhibitor use does not need to be deferred in patients with an indication for its use at hospital discharge.[8] For cardiogenic shock survivors with persistent reduced LVEF or HFrEF, SGLT2 inhibitors should be initiated as part of foundational GDMT when clinically appropriate.
Device therapy evaluation
Implantable cardioverter-defibrillator
Primary-prevention implantable cardioverter-defibrillator therapy is recommended in patients with nonischemic dilated cardiomyopathy or ischemic heart disease at least 40 days after myocardial infarction with LVEF ≤35% and NYHA class II or III symptoms on chronic GDMT, who have a reasonable expectation of meaningful survival for more than 1 year (class 1, level A). For patients at least 40 days after myocardial infarction with LVEF ≤30% and NYHA class I symptoms on GDMT, ICD therapy is also recommended (class 1, level B-R).[16]
The 2025 ACS guideline recommends ICD implantation in selected patients with LVEF ≤40% at least 40 days after myocardial infarction and at least 90 days after revascularization when criteria are met.[8] For cardiogenic shock survivors, reassessment is essential because ventricular recovery may occur after revascularization, myocarditis recovery, valve intervention, rhythm control, or GDMT optimization.
ICD implantation should not be performed early after acute myocardial infarction for primary prevention because early implantation has not improved prognosis. LVEF should be reassessed after stabilization, revascularization when applicable, and GDMT optimization before final ICD decisions.[16][8]
The usefulness of a temporary wearable cardioverter-defibrillator is uncertain in patients early after myocardial infarction with LVEF ≤35% (class 2b, level B-R per the 2025 ACS guideline). In the VEST trial, the wearable cardioverter-defibrillator did not significantly reduce the primary endpoint of arrhythmic death (relative risk 0.67; 95% CI 0.37-1.21), although all-cause mortality was nominally lower. Use may be considered in selected high-risk patients as a bridge to ICD eligibility assessment, particularly when device adherence is likely.[17][8]
Cardiac resynchronization therapy
Cardiac resynchronization therapy is recommended for patients with LVEF ≤35%, sinus rhythm, left bundle branch block, QRS duration ≥150 ms, and NYHA class II to ambulatory class IV symptoms despite GDMT.[16] CRT should be considered or individualized in selected patients with shorter QRS duration, non-LBBB morphology, pacing indication, or high expected ventricular pacing burden according to heart failure guideline criteria.[16]
Cardiac rehabilitation
The 2025 ACS guideline gives referral to outpatient cardiac rehabilitation before hospital discharge a class 1, level A recommendation for patients with ACS to reduce death, myocardial infarction, and hospital readmission and to improve functional status and quality of life. Home-based cardiac rehabilitation is a reasonable alternative when center-based programs are unavailable or inaccessible.[8]
Cardiogenic shock survivors may need modified rehabilitation for residual ventricular dysfunction, intensive care unit-acquired weakness, frailty, cognitive impairment, renal dysfunction, psychological distress, and deconditioning. Recovery-focused rehabilitation should be integrated into structured post-shock survivorship care.[1]
Risk-factor modification and survivorship care
| Domain | Secondary prevention approach |
|---|---|
| Smoking cessation | Complete cessation with behavioral counseling and pharmacotherapy when appropriate. |
| Blood pressure | Target office BP <130/80 mm Hg after hemodynamic stabilization, with individualized adjustment for frailty, orthostatic hypotension, renal function, and tolerance.[18] |
| Diabetes mellitus | Optimize glycemic control with cardioprotective agents when indicated, including SGLT2 inhibitors and GLP-1 receptor agonists in appropriate populations. |
| Weight management | Address overweight and obesity with lifestyle intervention and evidence-based weight management strategies. |
| Physical activity | Use cardiac rehabilitation as the foundation, then transition to regular activity adapted to functional status. |
| Diet | Heart-healthy dietary pattern; sodium restriction when heart failure or congestion is present. |
| Psychosocial health and PICS | Screen for depression, anxiety, post-traumatic stress, cognitive impairment, caregiver burden, and post-intensive care syndrome; refer for treatment when identified.[1] |
| Renal and hepatic recovery | Monitor kidney and liver function after shock-related hypoperfusion, congestion, contrast exposure, mechanical support, or nephrotoxic medication exposure. |
| Advanced heart failure risk | Reassess for durable LVAD, transplant, palliative care, or advanced heart failure referral when recurrent congestion, low-output symptoms, intolerance of GDMT, or repeated hospitalization persists. |
Palliative care integration
Early integration of palliative care is recommended for cardiogenic shock patients regardless of projected trajectory. Palliative care involvement should include advance care planning, identification of surrogate decision-makers, symptom management, and elicitation of patient and family values and goals.[19][20]
When temporary mechanical circulatory support cannot be weaned or recovery is unlikely, palliative care is important for discussions about durable LVAD candidacy, transplant candidacy, bridge-to-decision strategies, or transition to comfort-focused care.[21]
Palliative care consultation remains underused in the cardiac intensive care unit, including among high-risk patients with acute myocardial infarction complicated by cardiogenic shock.[20]
Structured post-discharge follow-up
Post-discharge care should be planned before hospital discharge and should include multidisciplinary follow-up, medication titration, functional recovery, device eligibility reassessment, palliative-care needs assessment, and psychosocial screening.[1]
Key elements include:
- Early follow-up within 1 to 2 weeks after discharge
- Review of shock etiology, revascularization status, ventricular function, renal function, and residual congestion
- GDMT titration toward target or maximally tolerated doses
- Laboratory monitoring after initiation or titration of RAAS inhibition, ARNI, mineralocorticoid receptor antagonist, diuretics, and SGLT2 inhibitor
- LVEF reassessment after stabilization and GDMT optimization
- ICD and CRT eligibility assessment at guideline-directed intervals
- Cardiac rehabilitation referral and participation tracking
- Screening for neurocognitive impairment, depression, anxiety, frailty, post-intensive care syndrome, and functional decline
- Evaluation for advanced heart failure therapies when recovery is incomplete or recurrent decompensation occurs
- Palliative-care involvement when symptom burden, treatment uncertainty, advanced therapies, or goals-of-care decisions are present
- Education on medication adherence, daily weights when heart failure is present, symptom monitoring, and when to seek urgent care
Practical secondary prevention approach
- Define the shock etiology and residual cardiac phenotype before discharge.
- Start or restart foundational HFrEF GDMT when hemodynamically tolerated.
- Use antiplatelet and antithrombotic therapy according to ACS, PCI, atrial fibrillation, LV thrombus, valve, or mechanical support-related indications.
- Prescribe high-intensity statin therapy after ACS unless contraindicated and intensify lipid therapy when LDL-C remains above guideline thresholds.
- Measure lipoprotein(a) at least once in adulthood, particularly in atherosclerotic cardiogenic shock survivors or those with premature or recurrent coronary events.
- Reassess beta-blocker need and duration according to LVEF, arrhythmia risk, ischemia, and heart failure status.
- Refer to cardiac rehabilitation before discharge after ACS or heart failure hospitalization when clinically feasible.
- Reassess LVEF after stabilization and GDMT optimization before ICD or CRT decisions.
- Arrange early multidisciplinary follow-up with laboratory monitoring and medication titration.
- Screen for cognitive, psychological, frailty, renal, hepatic, and functional sequelae of shock.
- Integrate palliative care when symptom burden, advanced therapy decisions, treatment uncertainty, or goals-of-care clarification are present.
- Refer early for advanced heart failure, durable MCS, transplant, or palliative care when recovery is incomplete or recurrent decompensation occurs.
Common pitfalls
- Discharging a cardiogenic shock survivor without a documented GDMT initiation and titration plan
- Treating discharge survival as recovery rather than the beginning of a high-risk survivorship phase
- Continuing to withhold beta blockers, RAAS inhibition, MRA, or SGLT2 inhibitor indefinitely after transient shock-related contraindications resolve
- Starting beta blockers before euvolemia or while the patient remains dependent on inotropes or vasopressors
- Failing to distinguish continuation of pre-existing beta-blocker therapy from new beta-blocker initiation after shock
- Failing to individualize antiplatelet and anticoagulant therapy in patients with high bleeding risk after mechanical circulatory support or vascular complications
- Omitting high-intensity statin therapy or nonstatin lipid intensification after ACS
- Listing inclisiran as equivalent to therapies with completed cardiovascular outcomes evidence
- Implanting a primary-prevention ICD too early after myocardial infarction or revascularization before reassessing LVEF after recovery and GDMT optimization
- Overstating the benefit of a wearable cardioverter-defibrillator despite uncertain benefit in early post-MI patients
- Failing to refer to cardiac rehabilitation because of deconditioning, frailty, or prior intensive care unit stay
- Not screening for depression, anxiety, post-traumatic stress, cognitive impairment, post-intensive care syndrome, and caregiver strain
- Delaying palliative care until end-of-life care rather than integrating it during high-risk decision-making
- Delaying advanced heart failure referral until irreversible end-organ dysfunction develops
References
- ↑ 1.0 1.1 1.2 1.3 Blumer V, Sinha SS, Carnicelli AP; et al. (2026). "Cardiogenic Shock Survivorship: A Multidisciplinary Approach Across the Continuum of Care". Journal of the American College of Cardiology. doi:10.1016/j.jacc.2026.02.5080.
- ↑ 2.0 2.1 Matsushita K, Delmas C, Marchandot B; et al. (2024). "Optimal Heart Failure Medical Therapy and Mortality in Survivors of Cardiogenic Shock: Insights From the FRENSHOCK Registry". Journal of the American Heart Association. 13 (5): e030975. doi:10.1161/JAHA.123.030975.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 Maddox TM, Januzzi JL, Allen LA; et al. (2024). "2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction". Journal of the American College of Cardiology. 83 (15): 1444–1488. doi:10.1016/j.jacc.2023.12.024.
- ↑ 4.0 4.1 Ostrominski JW, DeFilippis EM, Bansal K; et al. (2024). "Contemporary American and European Guidelines for Heart Failure Management". JACC: Heart Failure. 12 (5): 810–825. doi:10.1016/j.jchf.2024.02.020.
- ↑ Hollenberg SM, Stevenson LW, Ahmad T; et al. (2024). "2024 ACC Expert Consensus Decision Pathway on Clinical Assessment, Management, and Trajectory of Patients Hospitalized With Heart Failure Focused Update". Journal of the American College of Cardiology. 84 (13): 1241–1267. doi:10.1016/j.jacc.2024.06.002.
- ↑ Cardelli LS, Cherbi M, Huet F; et al. (2023). "Beta Blockers Improve Prognosis When Used Early in Patients With Cardiogenic Shock: An Analysis of the FRENSHOCK Multicenter Prospective Registry". Pharmaceuticals. 16 (12): 1740. doi:10.3390/ph16121740.
- ↑ van Diepen S, Katz JN, Albert NM; et al. (2017). "Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association". Circulation. 136 (16): e232–e268. doi:10.1161/CIR.0000000000000525.
- ↑ 8.0 8.1 8.2 8.3 8.4 8.5 8.6 8.7 8.8 Rao SV, O'Donoghue ML, Ruel M; et al. (2025). "2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes". Journal of the American College of Cardiology. doi:10.1016/j.jacc.2024.11.009.
- ↑ Virani SS, Newby LK, Arnold SV; et al. (2023). "2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease". Journal of the American College of Cardiology. 82 (9): 833–955. doi:10.1016/j.jacc.2023.04.003.
- ↑ Williams MS, Levine GN, Kalra D; et al. (2025). "2025 AHA/ACC Clinical Performance and Quality Measures for Patients With Chronic Coronary Disease". Journal of the American College of Cardiology. 85 (25): 2504–2535. doi:10.1016/j.jacc.2025.02.001.
- ↑ 11.0 11.1 Blumenthal RS, Morris PB, Gaudino M; et al. (2026). "2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia". Journal of the American College of Cardiology. doi:10.1016/j.jacc.2025.11.016.
- ↑ Wiggins BS, Barac A, Benziger CP; et al. (2026). "2026 Dyslipidemia Guideline-at-a-Glance". Journal of the American College of Cardiology. 87 (19): 2617–2623. doi:10.1016/j.jacc.2026.02.4872.
- ↑ Steg PG, Goodman SG, Jukema JW; et al. (2026). "Design of VICTORION-2 Prevent: A Randomized Double-Blind, Placebo-Controlled Trial Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease". American Heart Journal. 300: 107493. doi:10.1016/j.ahj.2026.107493.
- ↑ 14.0 14.1 Yndigegn T, Lindahl B, Mars K; et al. (2024). "Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction". The New England Journal of Medicine. 390 (15): 1372–1381. doi:10.1056/NEJMoa2401479.
- ↑ 15.0 15.1 Kristensen AMD, Rossello X, Atar D; et al. (2025). "Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction". The New England Journal of Medicine. doi:10.1056/NEJMoa2512686.
- ↑ 16.0 16.1 16.2 16.3 Heidenreich PA, Bozkurt B, Aguilar D; et al. (2022). "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure". Journal of the American College of Cardiology. 79 (17): e263–e421. doi:10.1016/j.jacc.2021.12.012.
- ↑ Olgin JE, Pletcher MJ, Vittinghoff E; et al. (2018). "Wearable Cardioverter-Defibrillator after Myocardial Infarction". The New England Journal of Medicine. 379 (13): 1205–1215. doi:10.1056/NEJMoa1800781.
- ↑ Jones DW, Ferdinand KC, Taler SJ; et al. (2025). "2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults". Journal of the American College of Cardiology. 86 (18): 1567–1678. doi:10.1016/j.jacc.2025.05.007.
- ↑ Blumer V, Kanwar MK, Barnett CF; et al. (2024). "Cardiogenic Shock in Older Adults: A Focus on Age-Associated Risks and Approach to Management". Circulation. 149 (14): e1051–e1065. doi:10.1161/CIR.0000000000001214.
- ↑ 20.0 20.1 Bohula EA, Landzberg MJ, Menon V; et al. (2025). "Palliative and End-of-Life Care During Critical Cardiovascular Illness: A Scientific Statement From the American Heart Association". Circulation. 151 (24): e1075–e1090. doi:10.1161/CIR.0000000000001334.
- ↑ Geller BJ, Sinha SS, Kapur NK; et al. (2022). "Escalating and De-Escalating Temporary Mechanical Circulatory Support in Cardiogenic Shock: A Scientific Statement From the American Heart Association". Circulation. 146 (6): e50–e68. doi:10.1161/CIR.0000000000001076.